You get paid in grocery money. The industry gets a multibillion-dollar product line. Between you and the drug, there's a chain of companies profiting at every link.
To understand what you're actually selling, it helps to follow the value chain from start to finish. Donated plasma does not go straight to a patient. It moves through four stages, and every stage is a business. Understanding that chain is the fastest way to see why your compensation is what it is — and why the industry can afford it.
Every link makes a margin off the same liter of fluid that left your arm. The question isn't whether there's money in plasma — it's where the money lands, and how little of it is yours.
Donor compensation in the United States is the most generous in the world by design — but "generous" is a relative word for a product that is sold on for a far larger sum. Here's the typical picture for a 2025–2026 donor:
Run the math. At the top of that range, a donor can gross roughly $5,000–6,000 a year by donating the FDA maximum, every week, all year. At the bottom of the industrial range, a single bottle of immune globulin can be $1,000+.
Those numbers are consistent with what the centers publish themselves. BioLife's compensation page and Octapharma's "earning potential" page describe per-visit pay and first-month bonuses in this same range, and independent pay guides — like Knocked-Up Money's breakdown of per-visit pay and monthly income — reach the same conclusion. The money you get is real, and it's what keeps donors coming back.
Now follow the same fluid up the chain. The U.S. collects the overwhelming majority of the world's plasma — roughly 70% of the global supply — because it is the only major developed country that pays donors. That dependence is not an accident; it is the foundation of the whole model.
So here is the asymmetry in a single line: you hand over a product that eventually becomes a drug priced at $1,000 a vial, and you're paid the price of a week's groceries. That gap isn't a secret — it's the business model.
The amount you're paid is not set by the value of your plasma. It's set by the price at which you'll keep coming back. The industry prices the donor relationship the way a store prices a loss leader: just enough to keep the supply steady, not enough to make donation genuinely lucrative.
The contrast with Europe makes the design explicit. European countries banned paid plasma donation on the principle that you shouldn't lure financially vulnerable people into selling parts of their body. The United States took the opposite route, and the FDA's own language carefully calls your payment compensation rather than purchase — a distinction that keeps the arrangement legal while still, in practice, paying donors. (For the full case, see who really pays.)
The result is a price that's pinned to a donor's rent, not to the medicine that comes out of their arm.
You might reasonably ask: if this is all so profitable, why not manufacture immune globulin in a lab and skip the donors altogether? The answer gets to the heart of why the paid-donor machine exists at all.
IVIG is a polyclonal antibody mixture — a cocktail of antibodies harvested from hundreds of thousands of different donors, each with their own distinct immune history. That diversity is the whole point. Immune globulin is used to treat immune deficiencies and autoimmune and neurological conditions precisely because it carries a broad, human-made immune defense that a single donor couldn't provide and a machine can't be taught to make. Clinical reviews of immunoglobulin therapy repeatedly cite its high cost and limited supply as a structural constraint — you can't simply scale it up on demand.
There is recombinant (lab-engineered) products for some clotting factors and for monoclonal antibodies — but no recombinant IVIG. The plasma-derived, polyclonal product has no synthetic equivalent. That is the one hard technical reason the industry needs donors at all: there is no substitute for the human raw material.
So the chain closes. Your plasma is the irreplaceable ingredient. The industry needs it, values it at the top of the chain, prices you at the bottom, and has no way to make the drug without bodies like yours.
Facts above are drawn from the sources below. Compensation figures reflect published 2025–2026 donor pay ranges; rates vary by center, region, and bonus structure.